Refine by
Cancer Systemic Therapy Service Provider
8 companies found
Service providerbased inWarren, NEW JERSEY (USA)
Auspex Diagnostics focuses on developing and providing advanced cancer diagnostics services to medical professionals and patients to help them personalize cancer treatment plans and improve patients’ quality of living. We started developing the ...
Auspex Diagnostic’s colorectal cancer test is a revolutionary treatment planning tool that can help stage II and III colorectal cancer patients and doctors personalize the treatment to the individual patient’s genes. Since no two ...
Service providerbased inSunnyvale, CALIFORNIA (USA)
Accuray is expanding radiation therapy: our products can deliver it accurately, precisely and effectively, from oncology to neuro-radiosurgery and beyond. Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, ...
Image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT) featuring integrated 3D image guidance, and highly conformal treatments enabled by a unique binary MLC. ...
Service providerbased inOrlando, FLORIDA (USA)
Asbestos.com is a website and advocacy group that helps the victims of asbestos exposure and their loved ones. We connect our visitors with the resources they need to understand and fight asbestos-related disease, all at no cost. We research the ...
Cryotherapy is a cancer treatment that kills cells by exposing them to extreme cold. Because living tissues cannot survive in drastically cold conditions, radiologists can use this therapy to induce hypothermia and kill solid tumors such as ...
Service providerbased inSan Diego, CALIFORNIA (USA)
CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for ...
CureMatch provides a scored and ranked listing of the most well-adapted personalized medicine treatment options. The comprehensive analysis considers commonly used treatments, as well as targeted therapy, immunotherapy, hormone therapy, and newly ...
Service providerbased inBaton Rouge, LOUISIANA (USA)
Oleander Medical Technologies is developing a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis ...
Targeted Osmotic Lysis (TOL) is a revolutionary treatment for advanced cancer, combining a generic drug (a cardiac glycoside) with a proprietary pulsed electric field ...
Service providerbased inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction ...
Service providerbased inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
IndivuType uses our highest quality biospecimens and clinical data, combined with leading-edge analytical methods, to offer a unique multi-omics database. Thus, providing new insights into the biology of cancer and enabling new discoveries in the ...
Service providerbased inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia ...